LENSAR, Inc. (NASDAQ:LNSR) Stock Holdings Boosted by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC increased its position in LENSAR, Inc. (NASDAQ:LNSR) by 18.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,890 shares of the company’s stock after acquiring an additional 6,184 shares during the period. Essex Investment Management Co. LLC owned approximately 0.34% of LENSAR worth $357,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC grew its position in LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after purchasing an additional 3,423 shares during the last quarter. Evernest Financial Advisors LLC bought a new position in LENSAR in the 4th quarter worth approximately $174,000. Bailard Inc. bought a new position in LENSAR in the 4th quarter worth approximately $181,000. Finally, Atria Investments Inc increased its position in LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after acquiring an additional 5,729 shares during the period. 40.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital boosted their price target on LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

LENSAR Stock Up 8.7 %

Shares of LNSR opened at $14.86 on Monday. The firm has a market capitalization of $175.18 million, a PE ratio of -10.18 and a beta of 0.62. The firm has a 50-day moving average price of $10.15 and a 200 day moving average price of $7.45. LENSAR, Inc. has a 52-week low of $2.67 and a 52-week high of $16.40.

LENSAR (NASDAQ:LNSR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The company had revenue of $16.73 million during the quarter, compared to the consensus estimate of $14.95 million.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.